Outcomes After Dose Intensification of Risankizumab for Crohn's Disease

Clin Gastroenterol Hepatol. 2024 Dec 9:S1542-3565(24)01067-X. doi: 10.1016/j.cgh.2024.09.039. Online ahead of print.

Authors

Rahul S Dalal¹, Heidy J Cabral², Alex Carlin², Matthew P Ilse², Jessica R Allegretti²

Affiliations

¹ Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address: rsdalal@bwh.harvard.edu.
² Division of Gastroenterology, Hepatology and Endoscopy, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA.

PMID: 39662691
DOI: 10.1016/j.cgh.2024.09.039

No abstract available

Keywords: biologic; dose escalation; effectiveness; inflammatory bowel disease.